Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis

Background Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF). However, current evidence on their efficacy and safety in this clinical setting remains limit...

Full description

Saved in:
Bibliographic Details
Main Authors: Miloud Cherbi, Olivier Lairez, Guillaume Baudry, Paul Gautier, François Roubille, Clément Delmas
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.039105
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849327869771120640
author Miloud Cherbi
Olivier Lairez
Guillaume Baudry
Paul Gautier
François Roubille
Clément Delmas
author_facet Miloud Cherbi
Olivier Lairez
Guillaume Baudry
Paul Gautier
François Roubille
Clément Delmas
author_sort Miloud Cherbi
collection DOAJ
description Background Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF). However, current evidence on their efficacy and safety in this clinical setting remains limited. Methods We performed a systematic review and meta‐analysis to assess efficacy/safety of early use of SGLT2is in AHF. PUBMED/EMBASE/Cochrane were searched from inception to May 31, 2024, for randomized controlled trials evaluating outcomes of SGLT2i early initiation in patients with AHF. Efficacy outcomes were all‐cause death and heart failure rehospitalizations. Safety outcomes included acute kidney injury, ketoacidosis, urinary tract infections, hypotension, and hypoglycemia. Early initiation was defined as performed before or shortly after discharge (within 3 days). A sensitivity analysis was conducted, including only patients with initiation before discharge. Results Seven randomized controlled trials that enrolled 2320 patients were included. Early use of SGLT2is was associated with a significant reduction in all‐cause death (odds ratio, 0.71 [95% CI, 0.55–0.92; 95% PI, 0.55–0.98]) and HF rehospitalizations (odds ratio, 0.73 [95% CI, 0.57–0.94; 95% PI, 0.58–0.93]), even after adjusting for follow‐up duration. SGLT2i initiation before discharge yielded consistent results for efficacy outcomes. Safety outcomes could not be usefully determined because of a low events rate resulting in wide CIs. The impact of diabetic status remains basically unknown due to the small number of available randomized controlled trials investigating this population. Conclusions Early introduction of SGLT2is in AHF improves all‐cause death and rehospitalization rates, can be performed before discharge, and should be offered to most patients with AHF.
format Article
id doaj-art-8c1ce3af0d6044cba27df45ccef5a307
institution Kabale University
issn 2047-9980
language English
publishDate 2025-04-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-8c1ce3af0d6044cba27df45ccef5a3072025-08-20T03:47:44ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-04-0114810.1161/JAHA.124.039105Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐AnalysisMiloud Cherbi0Olivier Lairez1Guillaume Baudry2Paul Gautier3François Roubille4Clément Delmas5Intensive Cardiac Care Unit Université Paul Sabatier ‐ Toulouse III Toulouse FranceIntensive Cardiac Care Unit Université Paul Sabatier ‐ Toulouse III Toulouse FranceUniversité de Lorraine, INSERM, Centre d’Investigations Cliniques Plurithématique, INSERM 1433, CHRU de Nancy, Institut Lorrain du Coeur et des Vaisseaux Nancy FranceIntensive Cardiac Care Unit Université Paul Sabatier ‐ Toulouse III Toulouse FranceCardiology Department Arnaud‐De‐Villeneuve Hospital Montpellier FranceIntensive Cardiac Care Unit Université Paul Sabatier ‐ Toulouse III Toulouse FranceBackground Observational studies and small randomized controlled trials have suggested the benefits of early introduction of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in acute heart failure (AHF). However, current evidence on their efficacy and safety in this clinical setting remains limited. Methods We performed a systematic review and meta‐analysis to assess efficacy/safety of early use of SGLT2is in AHF. PUBMED/EMBASE/Cochrane were searched from inception to May 31, 2024, for randomized controlled trials evaluating outcomes of SGLT2i early initiation in patients with AHF. Efficacy outcomes were all‐cause death and heart failure rehospitalizations. Safety outcomes included acute kidney injury, ketoacidosis, urinary tract infections, hypotension, and hypoglycemia. Early initiation was defined as performed before or shortly after discharge (within 3 days). A sensitivity analysis was conducted, including only patients with initiation before discharge. Results Seven randomized controlled trials that enrolled 2320 patients were included. Early use of SGLT2is was associated with a significant reduction in all‐cause death (odds ratio, 0.71 [95% CI, 0.55–0.92; 95% PI, 0.55–0.98]) and HF rehospitalizations (odds ratio, 0.73 [95% CI, 0.57–0.94; 95% PI, 0.58–0.93]), even after adjusting for follow‐up duration. SGLT2i initiation before discharge yielded consistent results for efficacy outcomes. Safety outcomes could not be usefully determined because of a low events rate resulting in wide CIs. The impact of diabetic status remains basically unknown due to the small number of available randomized controlled trials investigating this population. Conclusions Early introduction of SGLT2is in AHF improves all‐cause death and rehospitalization rates, can be performed before discharge, and should be offered to most patients with AHF.https://www.ahajournals.org/doi/10.1161/JAHA.124.039105acute heart failuredeathprognosissodium–glucose cotransporter 2 inhibitors
spellingShingle Miloud Cherbi
Olivier Lairez
Guillaume Baudry
Paul Gautier
François Roubille
Clément Delmas
Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
acute heart failure
death
prognosis
sodium–glucose cotransporter 2 inhibitors
title Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
title_full Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
title_fullStr Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
title_full_unstemmed Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
title_short Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
title_sort early initiation of sodium glucose cotransporter 2 inhibitors in acute heart failure a systematic review and meta analysis
topic acute heart failure
death
prognosis
sodium–glucose cotransporter 2 inhibitors
url https://www.ahajournals.org/doi/10.1161/JAHA.124.039105
work_keys_str_mv AT miloudcherbi earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis
AT olivierlairez earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis
AT guillaumebaudry earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis
AT paulgautier earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis
AT francoisroubille earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis
AT clementdelmas earlyinitiationofsodiumglucosecotransporter2inhibitorsinacuteheartfailureasystematicreviewandmetaanalysis